NYSEAMERICAN:IBIO iBio - IBIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.10 +0.05 (+2.44%) (As of 03/24/2023 08:51 PM ET) Add Compare Share Share Today's Range$1.95▼$2.2650-Day Range N/A52-Week Range$0.36▼$16.51Volume779,900 shsAverage Volume3.65 million shsMarket Capitalization$25.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About iBio (NYSEAMERICAN:IBIO) StockiBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.Read More Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBIO Stock News HeadlinesMarch 22, 2023 | reuters.comIBIO.C - | Stock Price & Latest News | ReutersFebruary 17, 2023 | investorplace.comWhy Is iBio (IBIO) Stock Up 124% Today?March 27, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 17, 2023 | benzinga.comWhy Nogin Shares Are Trading Higher By Around 77%; Here Are 20 Stocks Moving PremarketFebruary 16, 2023 | finance.yahoo.comiBio Announces MUC16 as its Latest Immune-Oncology Target ProgramFebruary 15, 2023 | investing.comJMP Securities Downgrades iBio, Inc. to Market PerformJanuary 5, 2023 | finance.yahoo.comiBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery EngineJanuary 2, 2023 | marketwatch.comWith 7% CAGR, Hereditary Angioedema Market 2023-2028 Find Out Essential Strategies To Expand The Business And Top Key Players | 93 Pages ReportMarch 27, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.December 17, 2022 | marketwatch.comiBio Inc. stock falls Thursday, underperforms marketDecember 17, 2022 | marketwatch.comiBio Inc. stock falls Thursday, underperforms marketDecember 9, 2022 | finance.yahoo.comiBio Announces Closing of $3.5 Million Underwritten Public OfferingDecember 7, 2022 | finance.yahoo.comiBio Announces Pricing of $3.5 Million Underwritten Public OfferingDecember 6, 2022 | finance.yahoo.comiBio Announces Proposed Underwritten Public OfferingDecember 6, 2022 | finance.yahoo.comiBio to Participate in the JMP Securities Hematology and Oncology SummitDecember 5, 2022 | finance.yahoo.comiBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022December 3, 2022 | finance.yahoo.comiBio Announces CEO DepartureNovember 3, 2022 | finance.yahoo.comiBio Accelerates Transformation to AI-Powered BiotechOctober 31, 2022 | finance.yahoo.comiBio, Inc. (IBIO)October 19, 2022 | investorplace.com7 Short-Squeeze Stocks to Sell Before Traders Cash Out - InvestorPlaceOctober 11, 2022 | uk.investing.comWhy ForgeRock Shares Are Trading Higher By Over 49%, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session By Benzinga - Investing.com UKOctober 10, 2022 | benzinga.comStocks That Hit 52-Week Lows On Monday - Teradyne (NASDAQ:TER), Teleflex (NYSE:TFX) - BenzingaOctober 7, 2022 | ft.comCamilla George: Ibio-Ibio album review — Sixties modernism with a west African-slant - Financial TimesSeptember 30, 2022 | investorplace.com3 Healthcare Stocks to Sell Before They Die - InvestorPlaceSeptember 28, 2022 | investing.comIbio Earnings, Revenue Miss in Q1 By Investing.com - Investing.comSeptember 28, 2022 | seekingalpha.comiBio is right to move away from COVID-19 vaccine development - CantorSeptember 28, 2022 | ca.investing.comIbio Earnings, Revenue miss in Q1 By Investing.com - Investing.com CanadaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBIO Company Calendar Last Earnings2/14/2023Today3/27/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:IBIO Previous SymbolNASDAQ:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone(979) 446-0027Fax302-356-1173Employees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,300,000.00 Net Margins-2,054.97% Pretax Margin-2,436.89% Return on Equity-106.69% Return on Assets-63.82% Debt Debt-to-Equity Ratio0.04 Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$2.38 million Price / Sales10.91 Cash FlowN/A Price / Cash FlowN/A Book Value$7.27 per share Price / Book0.29Miscellaneous Outstanding Shares12,370,000Free Float12,075,000Market Cap$25.98 million OptionableNot Optionable Beta-3.27 Key ExecutivesMartin B. BrennerChief Executive & Scientific OfficerMike JenkinsVice President-OperationsFelipe DuranCFO, Vice President-Financial Planning & AnalysisPhan DillonVice President, Head-Research & DevelopmentMatthew LuterVice President-Information TechnologyKey CompetitorsAmarillo BiosciencesOTCMKTS:AMARSELLAS Life Sciences GroupNASDAQ:SLSEvelo BiosciencesNASDAQ:EVLOAgeX TherapeuticsNYSE:AGETFF PharmaceuticalsNASDAQ:TFFPView All CompetitorsInstitutional OwnershipMillennium Management LLCSold 2,358,139 shares on 2/15/2023Ownership: 0.785%Renaissance Technologies LLCSold 906,232 shares on 2/13/2023Ownership: 4.235%Geode Capital Management LLCSold 1,945,078 shares on 2/13/2023Ownership: 0.847%Dimensional Fund Advisors LPBought 73,595 shares on 2/9/2023Ownership: 0.817%Group One Trading L.P.Sold 69,100 shares on 2/9/2023Ownership: 0.000%View All Institutional Transactions IBIO Stock - Frequently Asked Questions Should I buy or sell iBio stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IBIO, but not buy additional shares or sell existing shares. View IBIO analyst ratings or view top-rated stocks. Are investors shorting iBio? iBio saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 2,030,000 shares, a decrease of 5.6% from the February 13th total of 2,150,000 shares. Based on an average daily volume of 3,220,000 shares, the short-interest ratio is currently 0.6 days. Currently, 16.9% of the shares of the stock are sold short. View iBio's Short Interest. How were iBio's earnings last quarter? iBio, Inc. (NYSEAMERICAN:IBIO) issued its quarterly earnings results on Tuesday, February, 14th. The biotechnology company reported ($1.08) EPS for the quarter. iBio had a negative trailing twelve-month return on equity of 106.69% and a negative net margin of 2,054.97%. When did iBio's stock split? Shares of iBio reverse split on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA). What is iBio's stock symbol? iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO." Who are iBio's major shareholders? iBio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.24%), Geode Capital Management LLC (0.85%), Dimensional Fund Advisors LP (0.82%), Millennium Management LLC (0.78%), Simplex Trading LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Eastern Capital Ltd, James P Mullaney, Robert L Erwin and Robert Matthew Lutz. View institutional ownership trends. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is iBio's stock price today? One share of IBIO stock can currently be purchased for approximately $2.10. How much money does iBio make? iBio (NYSEAMERICAN:IBIO) has a market capitalization of $25.98 million and generates $2.38 million in revenue each year. How can I contact iBio? iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173. This page (NYSEAMERICAN:IBIO) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.